17 April, 2018 Resources

Pharma: a tale of rising demand and squeezed prices

Download the Document

Pharmaceuticals Sector Risk Report


Spending on prescription drugs is on an upward trajectory worldwide, and especially in Western Europe and the US. Pharma group profits rose by 2.9% in 2017. Reasons include ageing populations, changing lifestyles and pressure to access innovative treatments, and the rise comes despite the efforts of governments to control healthcare spending. The US situation is particularly uncertain, with the Trump administration’s attempts to repeal ‘Obamacare’ meeting difficulties.


Coface Regional Sector Risk Assessment

Strengths and weaknesses

Coface analysts predict research and development by pharmaceutical companies to pick up in 2018, and for prescription sales to grow – by 4% France, UK, Germany, Italy and Spain for example. This is driven by the rise in specialist drugs, which now amount to over a third of the total. Everywhere pharmaceutical companies are under pressure to provide discounts and lower prices by governments facing increasing demand. In the US alone, health insurance costs are likely to rise by as much as 18% in 2018.

Throughout the world healthcare provision is in flux and prices are being driven down. That’s why any company dealing with the pharma sector needs to have the best business data and insight on tap. It all comes free when you’re a Coface credit insurance policy holder.

Want to know how Coface can help your business know more and grow more?

Get in touch About us

Related resources


German Corporate Payment Survey 2020

German companies want to cash in as early as possible, according to the fourth edition of Coface’s survey on corporate payment experience in Germany, conducted in July and early-August 2020.

16 September, 2020

View Resource

Global renewable energies: continued rise despite the COVID-19 pandemic

In this context, integrating renewables into the grid is no longer optional for governments worldwide, in both advanced and emerging economies – even if they face strong headwinds in some regions.

09 September, 2020

View Resource

The Netherlands Corporate Payment Survey 2020

This study is the very first Coface survey on corporate payment experience in the Netherlands. Originally, this survey had been conducted between February and early-March 2020 (the first quarter of 2020, Q1 2020), with 301

02 September, 2020

View Resource


Keep your finger on the pulse with CofaNews

Sign up to CofaNews for the latest industry and economic news, exclusive invites and lots more.